Clinical and Translational Oncology - Breast cancer is the most common neoplasm in women and has the highest associated mortality rate. Rapid detection programmes can provide early diagnosis and...doi:10.1007/s12094-017-1731-1Bayo, J.Oncology Service, Huelva Hospital Complex, Huelva, SpainCastao,...
Breast cancer treatment is currently guided by the size of the primary tumor, whether it has spread to lymph nodes or other organs, and molecular markers, likeHER2, that open the door for targeted chemotherapies. But Lucci said cancer cells in the blood may be molecularly differ...
MiR-155 is another oncogenic miRNA that regulates multiple signaling pathways related to cell growth and survival;75it is known to targetBRCA1, a human breast cancer susceptibility gene76,77that is involved in DNA repair and cell cycle progression. Other genes associated with breast cancer progressio...
“This is the first success linking a solid tumor with blood biomarkers — an indicator of whether a patient will remain in remission,”Peter P. Lee, MD,chair of the department of immuno-oncology at City of Hope, said in a press release. “W...
Blood and neuroimaging biomarkers of cognitive sequelae in breast cancer patients throughout chemotherapy: A systematic reviewBiological markersBreast cancer... G Schroyen,J Vissers,A Smeets,... - 《Translational Oncology》 被引量: 0发表: 2022年 A novel computational predictive biological approach dis...
Fine-tuning AI Tools to Make Meaningful Predictions in Cancer Mary Caffrey Anant Madabhushi, PhD, of Emory University, told attendees at the International Myeloma Society 21st Annual Meeting & Exposition how AI's full potential in cancer care depends on its algorithms being validated by completed ...
Breast tumor subtypes are treated differently based on the status of molecular markers and associated class (i.e. basal-like, Luminal A, Luminal B, HER2-amplified). Standard therapy for estrogen receptor (ER) and/or progesterone receptor (PR)-positive tumors, which are also HER2 negative, are...
blood test can be reassured and encouraged to continue routine breast cancer screening. A positive test should alert the physician about the possible presence of a breast cancer not detected by routine screening mammography and drive to perform additional investigation, such as breast ultrasound and ...
Breast cancer starts as a local disease, but it can metastasize to the lymph nodes and distant organs. At primary diagnosis, prognostic markers are used to assess whether the transition to systemic disease is likely to have occurred. The prevailing model of metastasis reflects this view — it ...
Media coverage of a complex paper looking at epigenetic markers for breast cancer was widespread but too simplistic. Are the tests accurate and useful, asks Margaret McCartney , and where is the discussion of the potential harms?The Radio 4 Today programme heralded a day of wall to wall ...